Start a Value-Assessment Service for Radiology AI
People search: “how to start a health technology assessment service” (200+ per month)
Provide European-style health technology assessment (HTA) for radiology AI: independent clinical and economic value evaluation that complements safety-focused FDA clearance, a gap not yet filled at scale in the US.
Many people search for how to start a health technology assessment service every month, and most of what they find is fluff. This page is the honest version: what it really takes, what it costs, and how to start.
Keep browsing: All ideas · Top 10 · AI businesses · Free to start · More Health Tech
Difficulty
Advanced
Startup cost
$10,000 to $150,000 for health-economics and clinical expertise, methodology, and compliance
Time to first $
90 to 270 days
Revenue potential
High
Profit margin
45 to 70% on specialized health-economics consulting
Viability ⓘ
6.9 / 10
Search demand
Low (200+ per month on Google)
Where it runs
Online
Best for: Health economists and outcomes researchers building value assessment for medical AI
The ideaWhat this actually is
A radiology AI value assessment service evaluates whether an AI tool delivers clinical and economic value worth paying for, not just whether it is safe and works. FDA clearance answers safety and function, but not value. The 2025 JAMA review specifically recommended post-approval clinical and economic value assessment as a complement to safety-focused clearance. European-style health technology assessment (HTA) does exactly this and is not yet provided at scale in the US market.
The opportunityWhy this idea works
Health systems and payers increasingly want to know whether an AI tool is worth paying for, not just whether it is cleared, and no one provides US-style HTA for radiology AI at scale, so the gap is open. It is a specialized health-economics consulting service with 45 to 70 percent margin and low startup cost. As AI proliferates and budgets tighten, demand for rigorous value assessment grows, and the JAMA review explicitly called for it.
The openingWhy this idea is overlooked
Value assessment feels like a European regulatory concept rather than a US business, so people do not see it as an American service opportunity, leaving the gap open. FDA clearance answers safety and function, not value, and the 2025 JAMA review specifically recommended post-approval value assessment as a complement. Because HTA reads as foreign, the US market for radiology-AI value assessment is underserved.
The buildWhat you need to build this
| You need | Why it matters |
|---|---|
| Health-economics expertise | Assessing clinical and economic value requires health-economics methods (cost-effectiveness, budget impact), the core of the service. |
| Radiology clinical knowledge | Understanding the clinical value of an AI tool requires radiology domain knowledge alongside the economics. |
| An HTA-style methodology | A defensible value-assessment method, adapting European HTA to the US market, is the intellectual property of the service. |
| Access to clinical and cost data | Assessing value requires data on clinical outcomes and costs, so compliant data access is required. |
| Compliance and rigor | Value assessment must be rigorous and defensible to be trusted by systems and payers. |
| Low startup capital | Startup runs $10,000 to $150,000 for health-economics and clinical expertise, methodology, and compliance. |
How to start a health technology assessment service: the honest path
Consider the steps below our honest answer to how to start a health technology assessment service: what actually works, in the order it works.
🔒 The rest of the playbook is free
The step-by-step roadmap, the traps that kill this business, how it makes money, and your first 7 days. A free account unlocks every playbook forever, plus saving ideas and the tools to build this one.
Unlock the full playbook free →Already a member? Log in and this opens.
Create a free account to read the rest of the Start a Value-Assessment Service for Radiology AI playbook.
The shortcut
Where Unleash Your Ideas comes in
Unleash Your Ideas can help you adapt an HTA-style value-assessment methodology to the US market and target the systems, payers, and vendors who need radiology-AI value evidence.
Three ways to act on this idea
Do it yourself
Use the platform free to turn this idea into your own execution plan: niche, offer, money path, and first steps.
Unleash This Idea FreeGuided
Get our team's help shaping the strategy, the setup, and the launch path with you.
Get Help Setting It UpDone for you
Apply to have the strategy and buildout done with you or for you, with vetted specialists managed by one team.
Done For YouMake it yours
Customize this idea to me
Create your free account, Start a Value-Assessment Service for Radiology AI gets stored as YOURS, and Kenny, your AI build partner, rewrites the proven Unleash an Idea path around your version of it. Every idea you bring after this gets the same treatment.
✨ Customize this idea to me →Keep browsing
Related ideas
Start a Radiology AI Validation and Auditing Service →
Advanced · $10,000 to $150,000 for clinical and data-science expertise, validation methods, and compliance · Viability 7.4/10
Start a Radiology AI Performance-Heterogeneity Consultancy →
Advanced · $5,000 to $75,000 for analytics capability, methodology, and clinical expertise · Viability 7.0/10
Start a Legacy Radiology System Integration Firm →
Advanced · $5,000 to $100,000 for a specialist consultancy: mostly expertise, tooling, and compliance · Viability 7.3/10
Start a 510(k) Pathway Strategy Firm for Radiology AI →
Advanced · $5,000 to $100,000 for regulatory expertise, methodology, and compliance · Viability 7.2/10
Start a Medical Device Reimbursement and Market Access Consultancy →
Advanced · $1,000 to $12,000 · Viability 6.8/10
Start a Clinical Razor-and-Blade Reimbursement Strategy Consultancy →
Advanced · $5,000 to $40,000 to launch as a boutique consultancy · Viability 6.3/10
Questions
What people ask about this idea
Isn't FDA clearance enough to justify buying AI?
No. Clearance answers whether a tool is safe and works, not whether it delivers clinical and economic value worth paying for. The 2025 JAMA review specifically recommended post-approval value assessment as a complement to safety-focused clearance.
What is health technology assessment?
HTA evaluates the clinical and economic value of a technology, weighing outcomes against cost. It is common in Europe and does exactly what US radiology-AI buyers increasingly need, but it is not yet provided at scale in the US.
Who buys value assessment?
Health systems deciding what to buy, payers deciding what to cover, and AI vendors building value dossiers to support sales. All need evidence on whether a tool is worth its cost.
Why is it overlooked?
Value assessment reads as a European regulatory concept rather than a US business, so people do not see it as an American service opportunity, leaving the market underserved.